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The transcription factor Osterix (Sp7) is essential for osteoblastogenesis and bone formation in mice. Genome wide association studies
have demonstrated that Osterix is associated with bone mineral density in humans; however, the molecular signiﬁcance of Osterix in
human osteoblast differentiation is poorly described. In this study we have characterized the role of Osterix in human mesenchymal
progenitor cell (hMSC) differentiation. We ﬁrst analyzed temporal microarray data of primary hMSC treated with bone morphogenetic
protein-6 (BMP6) using clustering to identify genes that are associated with Osterix expression. Osterix clusters with a set of
osteoblast-associated extracellular matrix (ECM) genes, including bone sialoprotein (BSP) and a novel set of proteoglycans, osteomodulin
(OMD), osteoglycin, and asporin. Maximum expression of these genes is dependent upon both the concentration and duration of BMP6
exposure. Next we overexpressed and repressed Osterix in primary hMSC using retrovirus. The enforced expression of Osterix had
relatively minor effects on osteoblastic gene expression independent of exogenous BMP6. However, in the presence of BMP6, Osterix
overexpression enhanced expression of the aforementioned ECM genes. Additionally, Osterix overexpression enhanced BMP6 induced
osteoblast mineralization, while inhibiting hMSC proliferation. Conversely, Osterix knockdownmaintained hMSC in an immature state by
decreasing expression of these ECM genes and decreasing mineralization and hMSC proliferation. Overexpression of the Osterix
regulated geneOMDwith retrovirus promotedmineralization of hMSC. These results suggest thatOsterix is necessary, but not sufﬁcient
for hMSC osteoblast differentiation. Osterix regulates the expression of a set of ECM proteins which are involved in terminal osteoblast
differentiation.
J. Cell. Physiol. 227: 2677–2685, 2012.  2011 Wiley Periodicals, Inc.
Bone morphogenetic proteins (BMPs) form the largest
subgroup within the transforming growth factor beta (TGF-b)
super family of growth and differentiation regulatory proteins.
BMPs were originally identiﬁed as proteins capable of inducing
ectopic cartilage and bone formation upon local injection in
mammals [Reddi, 1992]. In cells of the osteoblast lineage, BMPs
induce expression of alkaline phosphatase, type I collagen, and
other noncollagenous bone proteins found in osteoid; a
phenotype consistent with differentiated osteoblasts [Cheifetz
et al., 1996; Cheng et al., 2003]. However, not every BMP family
member is able to induce bone differentiation to the same
degree. Previous studies demonstrated that the BMP family
member, BMP6, is selectively induced by glucocorticoid
treatment in human marrow-derived mesenchymal progenitor
cells (hMSC). BMP6 mRNA levels are approximately 16- to
22-fold higher in dexamethasone treated hMSC cells, while the
level of BMP2 is relatively unaffected [Diefenderfer et al., 2003;
Liu et al., 2004]. Also, signiﬁcantly lower quantities of BMP6
relative to BMP7 and BMP2 are required for healing of critical
size ulnar bone defects in rabbits. This may be attributed to
resistance of BMP6 to the BMP inhibitor, noggin. In comparison
to BMP2 and 7, this property of BMP6 is supported by
experiments showing that BMP6 carries a single amino acid
difference, which when introduced at the corresponding
positions in BMP2 and BMP7, results in their increased
resistance to noggin [Song et al., 2010].Wepreviously reported
that BMP6 was more potent and consistent than BMP2 and
BMP7 in inducing osteoblast differentiation in primary hMSC
[Friedman et al., 2006]. Taken together, these ﬁnding indicate
that effects of BMP6 may be unique among the BMP family in
mediating terminal osteoblast differentiation in human-derived
cells.
Osterix (SP7) is a zinc ﬁnger transcription factor speciﬁcally
expressed by osteoblasts which is required for osteoblast
differentiation in mice. Osterix-deﬁcient mice show an absence
of osteoblasts and no bone is formed [Nakashima et al., 2002].
Runx2, a transcription factor implicated in the control of
osteoblast differentiation, regulates Osterix transcription.
Runx2 is expressed in Osterix-deﬁcient mice, indicating that
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Osterix acts downstream of Runx2 [Celil et al., 2005].
Interestingly, Msx2 also regulatesOsterix expression in Runx2-
deﬁcient cells [Matsubara et al., 2008]. Osterix was found to
form a complex with the nuclear factor of activated T cells
(NFAT), promoting osteoblastic bone formation through the
activation of COLIA1 promoter activity [Koga et al., 2005].
Accordingly, constitutive activation of NFAT activates theWnt
signaling pathway, increasing bone formation and bone mass
[Winslow et al., 2006]. Interestingly, a number of recent
genome wide association studies (GWAS) have shown an
association between theOsterix locus and bone density in adults
and children [Timpson et al., 2009]; however, the mechanisms
of Osterix transcriptional activity and control of osteoblast
differentiation in humans are still poorly understood.
In our previous studies we have found that BMP6 treatment
of hMSC results in the pronounced expression of Osterix—
100s of fold higher than untreated cells—while having relatively
little effect on Runx2 expression [Friedman et al., 2006]. In the
present study, a microarray analysis was performed to evaluate
genes that change coincident with Osterix expression.
Retroviral mediated enforced overexpression and miRNA
mediated Osterix knockdown were conducted in hMSC to
determine the role of Osterix in human osteoblastogenesis.
We show that Osterix regulates a set of ECM genes involved in
terminal osteoblast differentiation, and that one of those
molecules, osteomodulin, promotes increased mineralization
when overexpressed in hMSC.
Material and Methods
Isolation and culture of human mesenchymal
stem cells
Primary hMSC were isolated from vertebral bodies obtained
through the National Disease Research Interchange (NDRI,
Philadelphia, PA) or extracted from mononuclear cells from
Lonza (Walkersville, MD), as previous reported [Friedman
et al., 2006]. Brieﬂy, bone marrow extracted from vertebral
bodies was placed in RPMI 1640 medium (Invitrogen, Grand
Island, NY) supplemented with 2% FBS. The bone marrow
suspension was layered over histopaque 1077 (Sigma, St. Louis,
MO) and centrifuged at 400g for 30min to obtain mononuclear
cells. Approximately 2 108 low density cells were placed in
assay medium with 20% deﬁned FBS (Hyclone, Logan, Utah).
Assay medium is McCoy’s 5a medium (Invitrogen)
supplemented to additionally contain 20mg/ml asparagine,
10mg/ml serine, 0.75MEM vitamins, 0.38MEM amino acids,
75mm non-essential amino acids, 100U/ml penicillin/
streptomycin, 2.3mM L-Glutamine, 1.3mM Sodium pyruvate,
0.06% sodium bicarbonate, 50mM BME (Invitrogen, Grand
Island, NY).
BMP6 treatment
Human mesenchymal stem cells (hMSCs) at passage 4 were
plated in 12-well dishes (1 104 perwell) and cultured for 1 day
in assay medium with 20% deﬁned FBS (Hyclone, Logan, Utah).
The next day, the medium was removed and the cells were
cultured in osteogenic medium, which is serum-free assay
medium additionally containing 1% ITS (BD Bioscience,
Bedford, MA), ascorbic acid (25mg/ml), and b-glycerol
phosphate (5mM). hMSC were treated with BMP6 (R&D
systems, Minneapolis, MN) and cultured for 0, 8, 24, and 96 h.
Then BMP6 was removed and washed out. Cells were
harvested at the indicated time points.
Microarray analysis
Clustering of gene expression data from an existing published
data base [Luo et al., 2011] was performed using the model
based clustering algorithm MCLUST to cluster genes with
common expression proﬁles across all time points and
treatment conditions. From these clustering results we could
identify patterns of genes that are repressed and activated by
BMP6 treatment and we identiﬁed a set of genes that clustered
with Osterix in a temporally dependent manner. Expression of
several genes that showed changes with microarray were
further validated using quantitative RT-PCR. These genes
included Osterix, KROX20, HEY1, HEY2, DLX5,
Osteomodulin (OMD), bone sialoprotein (BSP), and
osteocalcin (OCN) from at least three unique donors.
Retroviral overexpression
Full-length human cDNA sequence for Osterix (MHS1010-
98684613, OpenBiosystems, Huntsville, AL) was subcloned
into the murine myeloproliferative sarcoma virus-based
(MPSV) retroviral vector (PRLP2) vector. Stable retroviral
producer lines were established using a trans-infection method
as follows: Phoenix E cells were plated at a density of 2 104
cells/well of a 6-well plate and cultured overnight. On the
following day, the culture media were aspirated and exchanged
with fresh media (Dulbecco’s modiﬁed Eagle’s medium, high
glucose, 10% fetal bovine serum, penicillin/streptomycin, L-
glutamine). The phoenix E cells were transfected with 1mg of
either control retroviral empty vector PRLP2 or the PRLP2-
Osterixwith 2ml Lipofectamine 2000 (Invitrogen, Grand Island,
NY). The media were changed 8–10 h later and replaced with
fresh medium. On the following day, the media were changed
and the cells were placed at 378C, 5%CO2 overnight to harvest
viral supernatant on day 2 post-transfection. Fresh media were
added every 24 hrs until 4 days post-transfection. On day 1 of
transfection, the ecotropic retroviral packaging line, PG13, was
placed in a 6-well dish (2 104 cells/well) and cultured
overnight. On day 2, retroviral supernatant was harvested from
phoenix cells, ﬁltered (0.45mm), and supplemented with
polybrene (8mg/ml). Approximately 2ml of retroviral
supernatant was added to the PG13 cells on day 2 and again on
days 3 and 4. Stable producer lines were selected in puromycin
when applicable (2mg/ml). PG13 cells derived from this
protocol were considered stable retroviral producer cell lines
with an approximate viral titer of 1 107 colony-forming units/
ml. hMSC (passage 4) were plated in 6-well plates (2 104 cells/
well) and cultured overnight at 378C, 5%CO2.On the following
day, retroviral supernatantwas harvested fromPG13 ecotropic
retroviral producers, ﬁltered (0.45mm), and supplemented
with polybrene (8mg/ml). Alternatively, ﬁltered retroviral
supernatant was frozen, thawed, and supplemented with
polybrene. The hMSC were centrifuged for 90min at 1200 g
with 3ml of retroviral supernatant, and then the supernatant
replaced with fresh medium immediately. The procedure of
transduction was repeated the following day. On day 3, the
transduced hMSCwere trypsinized and plated to 12-well plates
at a concentration of 1 104 cells per well and cultured for
1 day in assay medium with 20% deﬁned FBS (Hyclone, Logan,
Utah). On day 4, the medium was removed and the cells were
cultured in osteogenic medium (descried above), before hMSC
were treated with BMP6 for 8, 24, or 96 h at 0, 2.5, and 10 nM.
Retroviral transduction for knockdown studies
The microRNAi based knockdown cassettes were designed
using the Invitrogen miRNAi designer tool (K4939-00,
Invitrogen, Grand Island, NY). miRNAi against Osterix (Target
sequence: AGAGGTTCACTCGTTCGGATG) was designed
and cloned into the pCDNA6.2 GW/miR vector. After
sequencing, the knockdown cassette was subcloned into
the PRLP2 retroviral vector. The production of retroviral
supernatant and transduction were performed as described
previously.
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Cell proliferation assay
To investigate the effect of BMP6 on cell proliferation, passage 4
hMSCwere plated at a concentration of 2 104 cells per well in
6-well plates and incubated in a 378C 5% CO2 incubator. The
following day, hMSC were cultured with 20% FBS in assay
mediumcontaining BMP6 (0, 2.5, 10 nM). The freshmediumwas
changed every 3 days. The cells were counted with a
hemocytometer (Electron Microscopy Sciences, Hatﬁeld, PA)
at 6, 12, 18 days.
To study the effects of Osterix on cell proliferation, the
transduced cells (forced overexpression, knock down, and
control) from two donors were plated at a concentration of
2 104 cells per well in 6-well plates and cultured in assay
mediumwith 20% serum. The freshmediumwas changed every
3 days. The cells were counted with a hemocytometer at 6, 12,
and 18 days.
Alizarin Red S staining
Cellswere harvested between days 12 and 16 (unless otherwise
indicated). The cells were washed in PBS and ﬁxed in 50%
ethanol for 5min. The ethanol solution was removed and an
Alizarin Red S solution (1%) was added for 5min. Each well was
rinsed three times with PBS.
Quantitative RT-PCR
1 104 cells were placed into each well of a 12-well plate and
cytokine induction studies were performed (as described
above). Total RNAwas isolated at various time points using the
RNeasy kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. RNA was dissolved in DEPC
ddH2O and stored at808C. All primers were designed using
the Primer3 program (Whitehead Institute, Cambridge, MA).
cDNAs were synthesized using Superscript III reverse
transcriptase (Invitrogen). Quantitative RT-PCR was
performed using an ABI 7600 Fast Thermocycler with SYBR
Green (BioWhittaker Molecular Application, Rockland, ME).
All reaction products were normalized to the expression level
of mRNA. PCR primer sets used were as follows: Osterix
forward, 50- TGC TTG AGG AGG AAG TTC AC -30; reverse,
50- AGG TCA CTG CCC ACA GAG TA -30; Osteomodulin
(OMD) forward, 50- TCC AAG AAA TTT GGA ACA CC -30;
reverse, 50- TGA CCA TTA GTG CTT CGT TG -30; Bone
sialoprotein (BSP) forward, 50- ACA ACA CTG GGC TAT
GGAGA -30; reverse, 50- CCT TGTTCGTTT TCA TCCAC -
30; Id1 forward, 50-CTC TAC GAC ATG AAC GGC TGT-30;
reverse, 50-TGC TCA CCT TGC GGT TCT G-30; b-actin
forward, 50- AGA CCTGTA CGCCAACAC AG -30; reverse,
50- CGA TCCACACGG AGT ACT TG -30. To ensure primer
speciﬁcity, melt curves were performed after 45 cycles of PCR.
Fold differences in gene expression were calculated using the
DDCt method with normalization to b-actin.
Western blot
Whole cell lysates were prepared from hMSC in 100ml lysis
buffer per well (M-PER Mammalian protein Extraction reagent
(Thermo Scientiﬁc, Rockford, IL, http://www.piercenet.com);
1 complete protease inhibitor (Roche Applied Science Roche
Diagnostics GmbH, Mannheim, Germany, https://www.roche-
applied-science.com)). The lysates were centrifuged for 10min
at 16,000g at 48C. Protein samples were electrophoresed
on a SDS polyacrylamide gel (NuPAGE 4–12% gradient gel;
Invitrogen) and were transferred onto a polyvinylidene
diﬂuoride membrane (Millipore, Billerica, MA). Membranes
were washed with TBS/0.1% Tween 20, and then blocked with
1% BSA (Fisher Scientiﬁc, Fair Lawn, NJ) in TBS/0.1% Tween 20
(Amersham Biosciences, Piscataway, NJ) for 30min at room
temperature. Primary antibodies including rabbit polyclonal
anti-P-Smad 1/5/8 (1:1000; Cell Signaling Technology, Beverly,
MA); rabbit polyclonal anti-SP7 (1:1000; Abcam,
Cambridge, U.K.); mouse monoclonal anti-HEY1 (1:1000;
Novus Biologicals, Littleton, CO); mouse monoclonal
anti-BSP(1:1000; CHEMICON International, Billerica, MA);
or mouse monoclonal anti-b-tubulin (1:10,000, SIGMA
ALDRICH, St. Louis, MO) were added to the membranes
overnight at 48C. Blots werewashed three timeswith TBS/0.1%
Tween 20 and followed by horseradish peroxidase-conjugated
anti-rabbit or anti-mouse secondary antibodies (Bio-Rad,
Hercules, CA) incubated for 1 h at room temperature. After
washing, the membrane was detected with ECL Detection
Reagents (Thermo Scientiﬁc, Rockford, IL) and exposed onto
X-ray ﬁlm (Denville Scientiﬁc INC, Metuchen, NJ).
Statistical analysis
Student’s t-tests were used to determine whether treated
groups, within donor, were signiﬁcantly different from controls
at P< 0.05.
Results
Osterix clusters with extracellular matrix (ECM) genes
during osteoblast differentiation
Previouslywe showed that 12 hof BMP6exposure induces gene
expression changes, including upregulation of the transcription
factor Osterix (SP7), consistent with osteoblast differentiation.
However, while short-term exposure to BMP6was sufﬁcient to
induce expression of some osteoblastic associated genes
(including Dlxs and Ids), short periods of treatment were not
sufﬁcient for maximal Osterix expression and osteoblast
differentiation as determined by mineral incorporation. A
maximal mineralization response was observed with 96 h of
BMP6 treatment [Friedman et al., 2006].
To better understand BMP6 regulation of hMSC osteoblast
differentiation and to determine genes with patterns of
expression similar to Osterix, we analyzed microarray data of
cells treated with 8, 24, or 96 h of BMP6 using cluster analysis.
The top 392 differentially expressed genes were sorted into
clusters based on similarities in the pattern of gene expression
(no change, up regulation, down regulation) at thirteen discrete
time points following control or BMP6 treatment. Genes were
sorted into 19 clusters based on BMP treatment duration,
harvest time point, and gene expression level and pattern
(Fig. 1 and Supplementary Fig. 1). Changes in gene expression in
various clusters are represented in the heatmap (Fig. 1A), while
normalized expression patterns are represented graphically in
Figure 1B,C and Supplementary Figure 1. Individual genes that
are present in each cluster are described in Supplementary
Tables 1–5. The clusters ﬁt several different patterns:
(i) Clusters 2,5,7,8,12,16,19 are BMP6-induced, but sustained
expression was dependent upon treatment duration (Induced/
Dependent) (Fig. 1C; Supplementary Fig. 1; Supplementary
Table 1), (ii) Clusters 13 and 15 are BMP6-induced but sustained
expression was independent of treatment duration (Induced/
Independent) (Fig. 1C; Supplementary Fig. 1; Supplementary
Table 2), (iii) Clusters 1,4, 10, 14, 18 are BMP6-repressed, but
sustained repression was dependent upon longer treatment
(Repressed/Dependent) (Fig. 1C; Supplementary Fig. 1;
Supplementary Table 3), (iv) Clusters 3, 6, and 9 are
BMP6-repressed but sustained repression was independent
of treatment length (Repressed/Independent) (Fig. 1C;
Supplementary Fig. 1; Supplementary Table 4), and (v) Clusters
11 and 17 are BMP6-induced highest at 8 h and expression is not
maintained, regardless of treatment duration (Early)
(Supplementary Fig. 1 and Supplementary Table 5).
The transcription factors DLX2, 3, and 5; Id1, 3, and 4;
and SMAD5 and 6 clustered together and were elevated with
only 8 h of BMP treatment and remained elevated for 10 days
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without any additional exogenous BMP (induced/duration
independent) (Supplementary Table 2). While 8 h of treatment
was sufﬁcient to induce the expression of the duration-
dependent genes, 96 h of treatment was required for high,
sustained expression of Osterix (represented in cluster 7)
and co-clustering genes throughout 10 days (induced/duration
dependent) (Supplementary Table 1). The ECM genes
osteopontin, bone sialoprotein (IBSP), aggrecan, syndecan 1,
osteomodulin (OMD), and glycoprotein M6B are located in
cluster 7withOsterix while the ECM genes osteoglycin (OGN)
and asporin (ASPN) are located in the very similar cluster 8,
showing expression patterns associated with terminal
osteoblast function (Supplementary Table 2).
Genes that are repressed and treatment-duration
dependent included a number of extracellular proteins that
may modify TGF-beta, Wnt, and IGF signaling, includingWISP1
and WISP2, follistatin (FST), IGFBP6 and 3, and SFRP4
(Supplementary Table 3). Genes that are repressed and
treatment-duration independent included, IGF1 and IGFBP2, as
well as inﬂammation and immune-associated genes and genes
associated with proteolysis (Supplementary Table 4). Finally,
there was a small number of genes expressed early with short-
term treatment, but down-regulated later including AMIGO2
and SCUBE3 (Supplementary Table 5). Results for speciﬁc
genes in these ﬁve primary clusters were validated by real-time
qPCR in 2–3 additional independent human donors MSC
isolates (data not shown).
To further investigate genes associated with Osterix
expression and the duration-dependent cluster we used
quantitative RT-PCR analysis to evaluate hMSC treated with
BMP6 or control vehicle for 8, 24, or 96 h and harvested for
RNA at 96 h. These investigations were performed under
deﬁned serum-free conditions. Under these conditions, hMSC
show little to no proliferation, while cells grown in 20% serum
double approximately every 6 days (results not shown).
Consistent with our microarray results, Osterix expression
is dependent on length of BMP6 treatment (Fig. 2A). Id1 on
the other hand, a transcription factor present in the duration-
independent cluster, shows a 20-fold increase with only 8 h of
treatment and the high-expression is maintained for 96 h with
8 h treatment (Fig. 2B). The mRNA level of osteoblast related
ECM proteins, BSP (Fig. 2C), OPN (data not shown), as well as
the proteoglycans OMD (Fig. 2D), ASPN (data not shown), and
OGN (data not shown), that were also present in the duration-
dependent cluster with Osterix showed a similar increase in a
time-dependent manner.
To verify these changes at the protein level we performed
Western blot analysis. BMP6 treatment induces R-smad1/5/8
phosphorylation and increases the expression of Osterix and
BSP at the protein level in a duration-dependent manner
(Fig. 2E).
BMP6 inhibits hMSC proliferation
BMP6 in serum-free culture conditions, as used in the previous
experiment, had no effect on cell number (data not shown);
however, we evaluated the effect of BMP6 on cell proliferation
by adding BMP6 ligand (0, 2.5, 10 nM) to hMSC cells that were
ﬁrst cultured for 24 h in 20% growth medium. Cell number was
counted at days 6, 12, and 18. BMP6 treated cells displayed 18%
less growth at day 6, 40% less growth at day 12 and 42% less
growth at day 18 than untreated cells at the same time points
(Fig. 2F). Similarly, in the presence of 10 nM BMP6, the growth
inhibitionwasmore signiﬁcant, 23% less at day 6, 53% less at day
12, and 61% less at day 18 (Fig. 2F). Taken together, BMP6
treatment, under serum conditions, decreased cell number in a
dose-dependent manner, consistent with cells undergoing
differentiation [Drozdoff et al., 1994; Kersten et al., 2005].
Enforced expression of Osterix does not induce human
osteoblast differentiation
To determine the role that Osterix plays in regulating co-
clustered ECM genes, retroviral transduction was used to
enforce expression of Osterix. Following plating and 48 h of
transduction, cells were treated with BMP6 (0, 2.5, 10 nM) for
4 days and RNA harvested for qRT-PCR analysis. Osterix gene
expression in the overexpressing cells was increased over
10,000-fold relative to control cells (Fig. 3A), which was
consistent with signiﬁcantly increased protein levels detected
usingWestern blot (Fig. 3C). Despite the substantial increase in
Osterix expression, there were relatively minor changes in the
expression of genes that clustered with Osterix, including
Fig. 1. BMP6 regulates a two-wave transcriptional process during
osteoblastdifferentiation.Expression resultswere clusteredusing the
model based clustering algorithmMCLUST across all time points and
treatment conditions. A: Heat map of the most signiﬁcant clusters.
B: ReferenceClustering Plot (in this case cluster 1). Circled points are
the control conditions where the expression level is essentially
constant. C: Representative proﬁles of the fourmost common cluster
patterns with BMP6 treatment. In some cases BMP6 treatment
induces expression (clusters 15 and 7) or represses expression
(clusters 6 and 1). For some proﬁles, removal of BMP6 treatment
results in expression reverting back to the control levels (e.g., clusters
15 and 1) (treatment duration dependent), while in other cases a
transient exposure of BMP6 is sufﬁcient to activate a pathway that
remains changed even after short-term BMP6 exposure and BMP6
removal (e.g., clusters 7 and 6) (duration independent). Refer to
Supplementary Figure 1 to view all 19 clusters and Supplementary
Tables 1–5 for speciﬁc genes located in these clusters. Differentially
expressed genes in clustered groupswere validatedusingquantitative
real-time PCR in 2–3 independent donor hMSC lines.
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OMD (Fig. 3B), BSP (Fig. 3C), ASPN (data not shown), andOPN
(data not shown), relative to control transfected cells. As well,
Osterix overexpression is not sufﬁcient for inducing in vitro
mineralization (Fig. 4A). However, when Osterix
overexpressing cells were treated with a suboptimal dose of
BMP6 (2.5 nM), osteogenic gene expression (Fig. 3B,C) and
mineralization was increased (Fig. 4A). This mineralization was
further increased inOsterix overexpressing cells treatedwith a
higher dose of BMP6 (10 nM). Collectively, these studies show
that Osterix alone is not sufﬁcient for driving osteoblast
differentiation, but promotes terminal differentiation in
conjunction with BMP-signaling.
Osterix is required for BMP6 induced hMSC osteoblast
differentiation
To determine whether Osterix expression was required for
BMP6-induced hMSC osteoblast differentiation and
mineralization, we used retrovirus-based microRNAi to knock
down expression of Osterix. Knockdown cells were infected
with Osterix miRNAi retrovirus, and control cells were
infected with an empty-vector (PRLP2) retrovirus. By qPCR,
Osterix expression level in knockdown cells was reduced
approximately 65% (donor 1) or 50% (donor 2) relative to the
control cells, and was also decreased with BMP6 exposure
(Fig. 5B). OMD (Fig. 5B), BSP (Fig. 5C), ASPN (results not
shown), and OPN (results not shown) were decreased with
Osterix knockdown. Compared to the vector transfected
control cells, the expression level of OMD was reduced about
40% (donor 1) or 90% (donor 2) with 2.5 nM BMP6 and about
50% (donor 1) or 90% (donor 2) with 10 nM BMP6 (Fig. 5B).
Furthermore, BSP was reduced 75% (donor 1) or 90% (donor
2) with 2.5 nM BMP6 treatment and 67% (donor 1) or 90%
(donor 2) with 10 nM BMP6 treatment (Fig. 5C). Osterix and
BSP protein level was also examined by Western blot and
demonstrated similar alterations (Fig. 5D). To examine the
effect of Osterix knockdown on osteoblast maturation, we
performed a mineralization assay. The Alizarin red S staining
results show that Osterix knockdown inhibits the effect of
BMP6 on mineralization (Fig. 4A).
Fig. 2. BMP6upregulatesOsterixandotherosteoblast genesdependentupontreatmentduration. hMSCweredifferentiated intoosteoblasts in
serum-free osteogenic medium and in the presence or absence of BMP6 (20 nM) for 8, 24, and 96 h, respectively. Real-time PCR analysis of the
relative expression of the transcription factors (A)Osterix and (B) Id1 and the extracellularmatrix proteins (C) bone sialoprotien (BSP) and (D)
osteomodulin (OMD).Thedata represent themeanvaluesWSDof triplicate experimentsnormalized to thehousekeepinggeneb-actin. F:BMP6
treatmentdecreaseshMSCproliferation.hMSCs(2T 104perwell in6-wellplates)werecultured intheassaymediumwith20%FBSinthepresence
of BMP6 at 0, 2.5, and 10nM. Cumulative cell number was counted at 6, 12, and 18 days. Statistical differences (M) of P<0.05 between the BMP6
treated and untreated cell lines were determined using t-test.
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Both Osterix overexpression and knockdown reduce
hMSC proliferation
Triplicate studies were performed to determine the effect of
Osterix on the proliferation of hMSC from two donors.
Following transduction, the retroviral constructs (PRLP2,
PRLP2-Osterix, and PRLP2-mirOsterix) transduced cells were
plated to the six-well plates at 2 104 cells/well with 20%
serum. The cell numbers were examined at day 6, 12, and
18. Donor 1 cells overexpressing Osterix showed 4% less
proliferation at day 6, 15% less at day 12, and 11% less at
day 18 as compared to vector control transfected cells at the
same time points (Fig. 4B). For donor 2 cells, our study showed
39% less proliferation day at 6, 35% less at day 12, and 20% less
at day 18 with Osterix overexpression as compared to vector
control transfected cells (Fig. 4B). We further examined
whether cell proliferation was affected by Osterix knockdown.
Surprisingly, as shown in Figure 5B, there was signiﬁcant
decrease in the proliferation of Osterix knockdown cells from
both the donors (Fig. 4B). Considered together these results
suggest that Osterix directly or indirectly regulates hMSC
proliferation and that the expression ofOsterix above or below
a certain threshold may decrease cell proliferation.
Enforced expression of OMD, a downstream gene of
Osterix, enhances BMP6 induced osteoblastogenesis
It is intriguing that a set of ECM proteins co-clusters with
Osterix and that Osterix regulates their expression. OMD is a
large proteoglycan that has previously been shown to be
produced by osteoblasts and we postulated that it might play a
role in Osterix-regulated terminal human osteoblast
maturation. Retroviral transduction was performed to enforce
OMDexpression in hMSC (Fig. 6A). BasalOMDexpressionwas
upregluated over 150-fold, and with BMP6 treatment levels
were 5–6-fold higher than in untreated cells. OMD
overexpressing hMSCs show higher mineralization compared
to the vector control cells (Fig. 6B), while having no signiﬁcant
effect on expression of other ECM genes (results not shown).
Discussion
The primary objective of this investigation was to explore
transcriptional events associated with BMP6 regulation of
hMSC osteoblast differentiation and to speciﬁcally determine
the role of Osterix. Clustering analysis demonstrates two-
waves of transcriptional activity that coincide with human
osteoblastogenesis. Genes that are expressed at a high level
with only 8 h of BMP treatment (duration independent), such as
Dlx2, 3, and 5 and Id1, 3, and 4 are in the ﬁrst wave of
expression, while Osterix clusters with a set of ECM genes,
such as osteomodulin and bone sialoprotein, that are in a
second wave (duration independent).
As a highly expressed transcription factor induced by BMP6
in hMSC, Osterix clearly plays an important role in the process
of terminal hMSC osteoblastogenesis. Intriguingly, recent
genome-wide association studies indicate that genetic variants
in the chromosomal region of Osterix are associated with
osteoporosis and bone mineral density (BMD) in children and
adults [Timpson et al., 2009]. In our study, Osterix enhances
BMP6-induced hMSCosteoblast differentiationwhile regulating
Fig. 3. EnforcedexpressionofOsterix increases theexpressionofosteoblast relatedextracellularmatrixprotein genes. hMSCwere transfected
with either PRLP2 control or PRLP2-Osterix retroviral supernatant and treated with BMP6 for 4 days. Quantitative real-time PCR was used to
demonstrate the effects ofOsterix expression onother duration-dependent genes in the absence of BMP2 andwith suboptimal 2.5 nMand 10nM
BMP6. A: Osterix, (B) BSP, (C) osteomodulin, (D)Western blot was performed to demonstrate that Osterix increased BSP protein level in the
osteogenicmediumwithBMP6for4daysat0,2.5,and10 nM.TheqPCRdatarepresentthemeanvaluesWSDoftriplicateexperimentsnormalized
to the housekeeping gene b-actin. Statistical differences (M) of P<0.05 between the Osterix-overexpressed and control PRLP2 cell lines were
determined using a t-test.
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the expression of co-clustering ECM genes. miRNA induced
knockdown of Osterix results in a reduction in BMP6 induced
hMSC mineralization that is associated with a decrease in
osteoblastic ECM gene expression.
Although the precise mechanisms of Osterix regulation of
osteoblastogenesis are yet to be determined, BMP signaling is
required for Osterix to have a signiﬁcant impact on osteoblast
maturation. Our functional studies show Osterix alone had a
relatively little effect on differentiation unless BMP6 signaling
was active. This result is similar to a previous study reporting
that Osterix induced osteogenic gene expression but not
differentiation in human fetal cells [Kurata et al., 2007]. In
contrast, overexpression ofOsterix alone is sufﬁcient to induce
osteogenic differentiation in vitro in murine embryonic stem
cells and primarymurine bonemarrowMSCs, but not inmurine
ﬁbroblasts [Kim et al., 2006; Tu et al., 2006]. In its role in
regulating terminal osteoblast differentiation Osterix likely
requires co-acting transcription factors or secondary post-
translation modiﬁcations for it to be fully effective. A recent
study by Ortuno et al. [2010] has shown that Osterix is
phosphorylated by p38 in response to BMP2 and that this
phosphorylation is required for maximal induction of
expression of BSP and ﬁbromodulin [Ortuno et al., 2010].
Additionally, Osterix has been shown to function cooperatively
with NFAT, and has been shown to promote the activation of
Col1a1 promoter [Koga et al., 2005].
Osterixwas found to up-regulate a set of ECMprotein genes,
including but not limited to BSP, OMD, OGN, and ASPN. The
regulation of BSP byOsterix is relatively well-described, at least
in murine cell lines [Ortuno et al., 2010], but Osterix has not
been shown to regulate these proteoglycans that are clustered
on chromosome 9. While the role of BSP in terminal human
osteoblast differentiation is described, the other genes are not
as well characterized. Recent work has shown that ASPN binds
to collagen and promotes mineralization in a MG63 cell line
[Kalamajski et al., 2009] and overexpression of osteomodulin
(also known as osteoadherin in mice) in MC3T3E1 cells
enhances osteoblast differentiation [Rehn et al., 2008]. We
extended the examination of the importance of genes regulated
by Osterix by overexpressing OMD in hMSC. In our study,
Alizarin red S staining data showed that OMD enhances BMP6
induced hMSC mineralization, indicating a possible role for
OMD in regulating mineralization in human primary cells.
It is intriguing that both enforced overexpression and
knockdown of Osterix decreased the growth of hMSC. The
negative effect of Osterix on proliferation is perhaps consistent
with decreased proliferation of cells as they progress through
osteoblast differentiation. A previous study has shown that the
inhibition of Wnt/b-catenin signaling by Osterix constitutes a
possible mechanism for the inhibition of osteoblast
proliferation [Zhang et al., 2008]. In contrast, other studies have
shown that the enforced expression of Osterix promotes the
proliferation ofmurine bonemarrow stromal cells andNIH3T3
cells [Kim et al., 2006; Tu et al., 2006]. This may reﬂect a
difference between cells obtained from mice and humans, or
could reﬂect differences in stage of differentiation. The ﬁnding
that knockdown of Osterix decreased growth of hMSC is
supported by a recent study demonstrating that there is an
Fig. 4. Osterix regulates hMSCosteoblastogenesis andproliferation.A:Left panel:Osterix-overexpressing andknockdownhMSCwere treated
withBMP6 for 96h at 0, 2.5, and 10 nM, and stainedwithAlizarin red S to evaluate calciumphosphatemineral, compare to the control cells. Right
panel: Alizarin red S stainedwells visualized using bright-ﬁeldmicroscopy. B: Transduced hMSC fromdonor 1 and donor 2were cultured in assay
mediumwith20%FBS(growthconditions).Cumulativecellnumberwascountedat6,12,and18days.Statisticaldifferences (M)ofP<0.05between
theOsterixoverexpressionorknockdownandcontrolPRLP2cell linesweredeterminedusing t-test. [Colorﬁgurecanbeseen intheonlineversion
of this article, available at http://wileyonlinelibrary.com/journal/jcp]
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Fig. 5. Osterix is required for BMP6 induced hMSCosteogenic differentiation. hMSCwere transfectedwithmir-Osterix retroviral supernatant
treated hMSC in the osteogenic medium with BMP6 for 4 days at 0, 2.5, and 10 nM. Real-time quantitative PCR analysis was performed to
demonstrate that knockdownof (A)Osterixonosteoblast associatedgenes (B)OMDand (C)BSPrelative to thevector controls.D:Westernblot
was performed to demonstrate that knockdown of Osterix decreased BSP protein level. The qPCR data represent the mean valuesWSD of
triplicate experiments normalized to the housekeeping gene b-actin. Statistical differences (M) of P<0.05 between the Osterix knockdown and
control PRLP2 cell lines were determined using t-test.
Fig. 6. Enforced expression of osteomodulin promotes BMP6 induced hMSC osteoblastogenesis. A: Real-time quantitative PCR analysis to
determineOMDexpressionlevel inthePRLP2-OMDretroviralsupernatanttreatedhMSCinosteogenicmediumwithBMP6for4daysat0,2.5,and
10 nM.B: Left panel:OMD-overexpressing hMSCwere treatedwithBMP6 for 96 h at 0, 2.5, and 10nM, and stainedwithAlizarin RedS to evaluate
calcium phosphate mineral, compared to the control cells. Right panel: OMD-overexpressing hMSC were stained with Alizarin Red S to
evaluate mineralization and visualized using bright-ﬁeld microscopy at 14th day. The Q-PCR data represent the mean valuesWSD of triplicate
experiments normalized to the housekeeping gene b-actin. Statistical differences (M) of P<0.05 between the Osterix knockdown and control
PRLP2 cell lines were determined using t-test. [Color ﬁgure can be seen in the online version of this article, available at http://
wileyonlinelibrary.com/journal/jcp]
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almost complete absence of bone marrow cells and excessive
mineralized cartilage in the femurs of postnatal Osterix
inactivated mouse [Zhou et al. 2010]. These ﬁndings suggest
that Osterix plays multiple functions in MSC proliferation at
different stages of differentiation.
We conclude that Osterix regulates a set of ECM proteins
that are involvedwith terminal osteoblast differentiation and/or
matrix mineralization. We hypothesize that Osterix acts as a
key mediator of terminal human osteoblast differentiation and
that a threshold of Osterix expression, both quantity and
duration, must be achieved for osteoblast maturation.
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